noteworthy treatments
neutralizing andibodies
prophylactic treatment
anti-viral and associate therapy
vaccines
anti-inflammatory
immuno-modulators
adjuvant therapy
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs (whatever the risk of bias)
All studies (RCT+OBS)
14-days deaths Emergency room visit or hospitalization death D28 death or transfer to ICU deaths deaths (time to event analysis only) hospitalization or death clinical deterioration clinical improvement clinical improvement (14-day) clinical improvement (28-day) clinical improvement (7-day) clinical improvement (time to event analysis only) death or ventilation hospital discharge hospitalization mechanical ventilation mechanical ventilation (time to event analysis only) radiologic improvement (14-day) symptomatic Covid-19 viral clearance viral clearance (time to event analysis only) viral clearance by day 14 viral clearance by day 7 ICU admission off oxygenation recovery AE leading to drug discontinuation serious adverse events superinfection acute kidney injury adverse events arrhythmia deep vein thrombosis elevated liver enzymes hyperbilirubinemia Myocardial infarction pulmonary embolism renal impairment serious adverse events (SAE), any venous thromboembolism
Interactive explorer of NMA results
1 Tang X, 2020 1 NIH NIAID ACTT-1, 2020 1 LIFESAVER, 2021 1 RECOVERY, 2022 1 BACC Bay Tocilizumab Trial, 2020 baricitinib vs. control
baricitinib better
0.87 [0.77; 0.98] 0.87 [0.77;0.98]baricitinib vs. control
baricitinib better
0.87 [0.77; 0.98] baricitinib vs. convalescent plasma treatment
0.44 [0.04; 5.38] 0.44 [0.04;5.38]baricitinib vs. convalescent plasma treatment
0.44 [0.04; 5.38] baricitinib vs. corticosteroids
0.89 [0.78; 1.01] 0.89 [0.78;1.01]baricitinib vs. corticosteroids
0.89 [0.78; 1.01] baricitinib vs. remdesivir
remdesivir better
1.58 [1.02; 2.44] 1.58 [1.02;2.44]baricitinib vs. remdesivir
remdesivir better
1.58 [1.02; 2.44] baricitinib vs. tocilizumab
0.57 [0.15; 2.13] 0.57 [0.15;2.13]baricitinib vs. tocilizumab
0.57 [0.15; 2.13] control vs. baricitinib
baricitinib better
1.15 [1.02; 1.30] 1.15 [1.02;1.30]control vs. baricitinib
baricitinib better
1.15 [1.02; 1.30] control vs. convalescent plasma treatment
0.50 [0.04; 6.17] 0.50 [0.04;6.17]control vs. convalescent plasma treatment
0.50 [0.04; 6.17] control vs. corticosteroids
1.02 [0.98; 1.07] 1.02 [0.98;1.07]control vs. corticosteroids
1.02 [0.98; 1.07] control vs. remdesivir
remdesivir better
1.82 [1.20; 2.76] 1.82 [1.20;2.76]control vs. remdesivir
remdesivir better
1.82 [1.20; 2.76] control vs. tocilizumab
0.66 [0.18; 2.43] 0.66 [0.18;2.43]control vs. tocilizumab
0.66 [0.18; 2.43] convalescent plasma treatment vs. baricitinib
2.30 [0.19; 28.43] 2.30 [0.19;28.43]convalescent plasma treatment vs. baricitinib
2.30 [0.19; 28.43] convalescent plasma treatment vs. control
2.00 [0.16; 24.66] 2.00 [0.16;24.66]convalescent plasma treatment vs. control
2.00 [0.16; 24.66] convalescent plasma treatment vs. corticosteroids
2.05 [0.17; 25.25] 2.05 [0.17;25.25]convalescent plasma treatment vs. corticosteroids
2.05 [0.17; 25.25] convalescent plasma treatment vs. remdesivir
3.64 [0.28; 46.41] 3.64 [0.28;46.41]convalescent plasma treatment vs. remdesivir
3.64 [0.28; 46.41] convalescent plasma treatment vs. tocilizumab
1.32 [0.08; 22.35] 1.32 [0.08;22.35]convalescent plasma treatment vs. tocilizumab
1.32 [0.08; 22.35] corticosteroids vs. baricitinib
1.12 [0.99; 1.28] 1.12 [0.99;1.28]corticosteroids vs. baricitinib
1.12 [0.99; 1.28] corticosteroids vs. control
0.98 [0.93; 1.02] 0.98 [0.93;1.02]corticosteroids vs. control
0.98 [0.93; 1.02] corticosteroids vs. convalescent plasma treatment
0.49 [0.04; 6.03] 0.49 [0.04;6.03]corticosteroids vs. convalescent plasma treatment
0.49 [0.04; 6.03] corticosteroids vs. remdesivir
remdesivir better
1.78 [1.17; 2.70] 1.78 [1.17;2.70]corticosteroids vs. remdesivir
remdesivir better
1.78 [1.17; 2.70] corticosteroids vs. tocilizumab
0.64 [0.17; 2.38] 0.64 [0.17;2.38]corticosteroids vs. tocilizumab
0.64 [0.17; 2.38] remdesivir vs. baricitinib
remdesivir better
0.63 [0.41; 0.98] 0.63 [0.41;0.98]remdesivir vs. baricitinib
remdesivir better
0.63 [0.41; 0.98] remdesivir vs. control
remdesivir better
0.55 [0.36; 0.84] 0.55 [0.36;0.84]remdesivir vs. control
remdesivir better
0.55 [0.36; 0.84] remdesivir vs. convalescent plasma treatment
0.28 [0.02; 3.51] 0.28 [0.02;3.51]remdesivir vs. convalescent plasma treatment
0.28 [0.02; 3.51] remdesivir vs. corticosteroids
remdesivir better
0.56 [0.37; 0.86] 0.56 [0.37;0.86]remdesivir vs. corticosteroids
remdesivir better
0.56 [0.37; 0.86] remdesivir vs. tocilizumab
0.36 [0.09; 1.43] 0.36 [0.09;1.43]remdesivir vs. tocilizumab
0.36 [0.09; 1.43] tocilizumab vs. baricitinib
1.75 [0.47; 6.50] 1.75 [0.47;6.50]tocilizumab vs. baricitinib
1.75 [0.47; 6.50] tocilizumab vs. control
1.52 [0.41; 5.62] 1.52 [0.41;5.62]tocilizumab vs. control
1.52 [0.41; 5.62] tocilizumab vs. convalescent plasma treatment
0.76 [0.04; 12.91] 0.76 [0.04;12.91]tocilizumab vs. convalescent plasma treatment
0.76 [0.04; 12.91] tocilizumab vs. corticosteroids
1.56 [0.42; 5.76] 1.56 [0.42;5.76]tocilizumab vs. corticosteroids
1.56 [0.42; 5.76] tocilizumab vs. remdesivir
2.76 [0.70; 10.91] 2.76 [0.70;10.91]tocilizumab vs. remdesivir
2.76 [0.70; 10.91] Risk of bias:
- high: 0.0 %
- some concerns: 100.0 %
- low: 0.0 %
- NA: 0.0 % corticosteroids Risk of bias:
- high: 0.0 %
- some concerns: 100.0 %
- low: 0.0 %
- NA: 0.0 % remdesivir Risk of bias:
- high: 0.0 %
- some concerns: 0.0 %
- low: 100.0 %
- NA: 0.0 % convalescent plasma treatment Risk of bias:
- high: 0.0 %
- some concerns: 100.0 %
- low: 0.0 %
- NA: 0.0 % baricitinib Risk of bias:
- high: NaN
- some concerns: NaN
- low: NaN
- NA: NaN tofacitinib Risk of bias:
- high: NaN
- some concerns: NaN
- low: NaN
- NA: NaN casirivimab/imdevimab (Ronapreve) Risk of bias:
- high: NaN
- some concerns: NaN
- low: NaN
- NA: NaN interferon Risk of bias:
- high: 0.0 %
- some concerns: 0.0 %
- low: 100.0 %
- NA: 0.0 % tocilizumab Risk of bias:
- high: NaN
- some concerns: NaN
- low: NaN
- NA: NaN sarilumab Risk of bias:
- high: NaN
- some concerns: NaN
- low: NaN
- NA: NaN control direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI ROB: high some concerns low NA
Click on treatment name to display related network evidence
